



PRESS
RELEASE

Ambu announces CE mark of fifth generation single-use bronchoscope

Ambu enters a segment of 3 million annual procedures, extending market leadership in pulmonology.

Today, Ambu announces that Ambu® aScope™ 5 Broncho, a family of single-use sterile bronchoscopes, has received European regulatory clearance. This is the fifth generation of bronchoscopes since Ambu established the single-use flexible bronchoscopy market in 2009. Since then, Ambu expanded the market in the Operating Room (OR) and Intensive Care Unit (ICU), market segments representing 3 million procedures.

Entering a new market segment of 3 million procedures

Now, with the launch of aScope 5 Broncho, Ambu will enter into the Bronchoscopy Suite, an untapped segment of 3 million more procedures where high image quality and handling performance are key, and where workflow and patient safety play an important role. To enter this market, the aScope 5 Broncho family has advanced imaging and design features, including a new high-resolution camera chip, which in combination with the full HD Ambu® aBox™ 2 processing unit, delivers superior image quality. The convenience and availability of aScope 5 Broncho also supports healthcare systems in their efforts to overcome staff shortages and workflow challenges. Finally, the sterile offering provides a solution to the growing cross-contamination risks.

“For the first time, I have been presented with a single-use bronchoscope that meets the high requirements needed for the advanced procedures I perform in the bronchoscopy suite,” says Dr. med. Wolfgang Hohenforst-Schmidt¹, Lungenzentrum Bamberg, Germany.

With CE Mark, Ambu will proceed with commercialisation of the aScope 5 Broncho and aBox 2 in Europe, with other markets to follow. In line with the advanced technology and product performance, Ambu will commercialize aScope 5 Broncho at a price premium to the existing aScope™ 4 Broncho portfolio.

Extending market leadership in pulmonology

The launch of the aScope 5 Broncho family represents the next step in Ambu’s innovation agenda in pulmonology. It will be followed later this year by additional launches to expand the aScope 5 Broncho family’s size range, a new award-winning specimen sampling system (aScope™ 5 Broncho Sampler Set), and a next-generation videolaryngoscope. Together with the recent launch of VivaSight 2, these will give Ambu the most comprehensive single-use visualization portfolio in pulmonology, all centered around our aBox 2 and aView 2 Advance ecosystem.

“We introduced the world’s first flexible single-use bronchoscope thirteen years ago, and since then, single-use bronchoscopes have been widely adopted in the ICU and in the OR,” says Juan Jose Gonzalez, CEO of Ambu A/S. *“However, until now, the advanced needs in the bronchoscopy suite have not been met by single-use scopes. In aScope 5 Broncho we believe we have created a bronchoscope that is on par with reusable bronchoscopes, and in some areas even superior. This is an important milestone and shows the power of our innovation engine. The technology in our aScope 5 Broncho will set a new benchmark in terms of image quality and functionality and will power all of our next-generation launches. Our innovation agenda within pulmonology will extend Ambu’s position as the world’s most innovative single-use endoscopy player.”*

¹ Dr. Hohenforst-Schmidt is a paid consultant of Ambu A/S. He has not been compensated for his quote in this press release.



Ambu® aScope™ 5 Broncho, the new generation of single-use bronchoscopes, and Ambu® aBox™ 2

Contacts

Media

Mikkel Trier Wagner, Director, Corporate Communications, mtw@ambu.com / +45 4191 0830

Investors

Nicolai Thomsen, Director, Investor Relations & Strategic Financial Planning, nith@ambu.com / +45 2620 8047

Ambu A/S

Baltorpbakken 13, DK-2750 Ballerup, Denmark, Tel.: +45 7225 2000, CVR no.: 63 64 49 19, www.ambu.com

About Ambu

Ambu has been bringing the solutions of the future to life since 1937. Today, millions of patients and healthcare professionals worldwide depend on the efficiency, safety and performance of our single-use endoscopy, anaesthesia, and patient monitoring solutions. We continuously look to the future with a commitment to deliver innovative quality products that have a positive impact on patient care and the work of healthcare professionals. Headquartered near Copenhagen in Denmark, Ambu employs approximately 4,500 people in Europe, North America and the Asia Pacific. For more information, please visit ambu.com or ambuUSA.com or follow us on our [corporate LinkedIn](#) and [USA LinkedIn](#) pages.